• Explore /
  • Poster
  • / A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.

A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.

Abstract Poster

Authors

null

Jayesh Desai

Royal Melbourne Hospital, Melbourne, Australia

Jayesh Desai , Ben Markman , Shahneen Kaur Sandhu , Hui Kong Gan , Michael Friedlander , Ben Tran , Tarek Meniawy , Vishal Boolell , Duncan Colyer , Christie Norris , Malaka Ameratunga , Jason Yang , Kang Li , Lai Wang , Lusong Luo , Zhen Qin , Michael Millward

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT02407990

Citation

J Clin Oncol 34, 2016 (suppl; abstr 3066)

DOI

10.1200/JCO.2016.34.15_suppl.3066

Abstract #

3066

Poster Bd #

388

Abstract Disclosures

Similar Posters

First Author: Patrick Alexander Ott

First Author: Sophia Frentzas

First Author: Thorsten Oliver Goetze

First Author: Jermaine Coward